导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.19% | 3821/4763 |
| 近一周 | -2.94% | 4408/5452 |
| 近一月 | -6.70% | 4281/5409 |
| 近一季 | 0.90% | 810/5219 |
| 近半年 | -10.64% | 3700/4908 |
| 近一年 | -15.79% | 3772/4388 |
| 近两年 | -0.06% | 2884/2951 |
| 近三年 | -20.66% | 2165/2250 |
| 成立以来 | 4.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.25% 3092/4961 |
-12.48% 4404/5312 |
- - |
- - |
| 2025 | -4.33% 3361/4813 |
-4.71% 3216/3635 |
1.10% 2464/4076 |
1.89% 3853/4524 |
-2.53% 3165/4813 |
| 2024 | -5.50% 2270/3463 |
-4.02% 1601/2808 |
-6.46% 1956/3014 |
12.32% 2374/3129 |
-6.29% 2643/3463 |
| 2023 | 0.77% 390/2656 |
11.60% 329/2280 |
0.11% 340/2385 |
-5.68% 1355/2515 |
-4.37% 989/2655 |
| 2022 | -10.31% 203/2207 |
-3.70% 160/1919 |
-5.78% 1872/2016 |
-14.18% 1042/2113 |
15.19% 71/2208 |
| 2021 | 39.00% 38/1822 |
0.81% 276/1255 |
23.13% 118/1330 |
-10.01% 1205/1466 |
24.44% 6/1822 |
| 2020 | 20.33% 718/1250 |
-1.94% 249/1028 |
18.45% 334/1067 |
6.10% 876/1164 |
-2.35% 1121/1184 |
| 2019 | 5.53% 752/1092 |
19.84% 618/754 |
-8.74% 607/804 |
-6.23% 810/850 |
2.90% 851/918 |
| 2018 | -27.02% 412/834 |
- - |
- - |
- - |
-16.44% 637/691 |
| 2017 | 0.64% 473/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证中药ETF联接(LOF)C VS. 长安沪深300非周期A(740101) |